Impact of sex on use of low tidal volume ventilation in invasively ventilated ICU patients-A mediation analysis using two observational cohorts.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
16
03
2021
accepted:
15
06
2021
entrez:
14
7
2021
pubmed:
15
7
2021
medline:
17
11
2021
Statut:
epublish
Résumé
Studies in patients receiving invasive ventilation show important differences in use of low tidal volume (VT) ventilation (LTVV) between females and males. The aims of this study were to describe temporal changes in VT and to determine what factors drive the sex difference in use of LTVV. This is a posthoc analysis of 2 large longitudinal projects in 59 ICUs in the United States, the 'Medical information Mart for Intensive Care III' (MIMIC III) and the 'eICU Collaborative Research DataBase'. The proportion of patients under LTVV (median VT < 8 ml/kg PBW), was the primary outcome. Mediation analysis, a method to dissect total effect into direct and indirect effects, was used to understand which factors drive the sex difference. We included 3614 (44%) females and 4593 (56%) males. Median VT declined over the years, but with a persistent difference between females (from median 10.2 (9.1 to 11.4) to 8.2 (7.5 to 9.1) ml/kg PBW) vs. males (from median 9.2 [IQR 8.2 to 10.1] to 7.3 [IQR 6.6 to 8.0] ml/kg PBW) (P < .001). In females versus males, use of LTVV increased from 5 to 50% versus from 12 to 78% (difference, -27% [-29% to -25%]; P < .001). The sex difference was mainly driven by patients' body height and actual body weight (adjusted average causal mediation effect, -30% [-33% to -27%]; P < .001, and 4 [3% to 4%]; P < .001). While LTVV is increasingly used in females and males, females continue to receive LTVV less often than males. The sex difference is mainly driven by patients' body height and actual body weight, and not necessarily by sex. Use of LTVV in females could improve by paying more attention to a correct calculation of VT, i.e., using the correct body height.
Sections du résumé
BACKGROUND
Studies in patients receiving invasive ventilation show important differences in use of low tidal volume (VT) ventilation (LTVV) between females and males. The aims of this study were to describe temporal changes in VT and to determine what factors drive the sex difference in use of LTVV.
METHODS AND FINDINGS
This is a posthoc analysis of 2 large longitudinal projects in 59 ICUs in the United States, the 'Medical information Mart for Intensive Care III' (MIMIC III) and the 'eICU Collaborative Research DataBase'. The proportion of patients under LTVV (median VT < 8 ml/kg PBW), was the primary outcome. Mediation analysis, a method to dissect total effect into direct and indirect effects, was used to understand which factors drive the sex difference. We included 3614 (44%) females and 4593 (56%) males. Median VT declined over the years, but with a persistent difference between females (from median 10.2 (9.1 to 11.4) to 8.2 (7.5 to 9.1) ml/kg PBW) vs. males (from median 9.2 [IQR 8.2 to 10.1] to 7.3 [IQR 6.6 to 8.0] ml/kg PBW) (P < .001). In females versus males, use of LTVV increased from 5 to 50% versus from 12 to 78% (difference, -27% [-29% to -25%]; P < .001). The sex difference was mainly driven by patients' body height and actual body weight (adjusted average causal mediation effect, -30% [-33% to -27%]; P < .001, and 4 [3% to 4%]; P < .001).
CONCLUSIONS
While LTVV is increasingly used in females and males, females continue to receive LTVV less often than males. The sex difference is mainly driven by patients' body height and actual body weight, and not necessarily by sex. Use of LTVV in females could improve by paying more attention to a correct calculation of VT, i.e., using the correct body height.
Identifiants
pubmed: 34260619
doi: 10.1371/journal.pone.0253933
pii: PONE-D-21-08610
pmc: PMC8279424
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0253933Déclaration de conflit d'intérêts
Ary Serpa Neto reported receiving personal fees from Dräger outside of the submitted work. Marcelo Gama de Abreu reported receiving grants and personal fees from Drägerwerk AG and GlaxoSmithKline and receiving personal fees from GE Healthcare outside of the submitted work. No other disclosures were reported. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
J Intensive Care Soc. 2016 Aug;17(3):191-195
pubmed: 28979490
Anesthesiology. 2015 Jul;123(1):66-78
pubmed: 25978326
Am J Emerg Med. 2017 Dec;35(12):1963-1964
pubmed: 28610772
J Crit Care. 2012 Jun;27(3):323.e1-9
pubmed: 21855285
Anesth Analg. 2019 Jul;129(1):129-140
pubmed: 30222649
JAMA. 2012 Oct 24;308(16):1689-90
pubmed: 23093167
PLoS One. 2018 Jun 29;13(6):e0199917
pubmed: 29958278
Intensive Care Med. 2018 May;44(5):564-577
pubmed: 29632996
Crit Care. 2019 Dec 27;23(1):424
pubmed: 31881909
Intensive Care Med. 2013 Jan;39(1):3-5
pubmed: 23179334
Anesthesiology. 2012 May;116(5):1072-82
pubmed: 22450472
Crit Care Med. 2004 Sep;32(9):1817-24
pubmed: 15343007
Intensive Care Med. 2005 Apr;31(4):540-6
pubmed: 15731892
Intensive Care Med Exp. 2018 Oct 19;6(Suppl 2):40
pubmed: 30341496
BMC Anesthesiol. 2015 Mar 28;15:40
pubmed: 25852301
Ann Intensive Care. 2016 Dec;6(1):55
pubmed: 27325410
N Engl J Med. 2000 May 4;342(18):1301-8
pubmed: 10793162
Circulation. 2000 Jun 13;101(23):E215-20
pubmed: 10851218
Crit Care Med. 2006 Aug;34(8):2153-7
pubmed: 16763505
Intensive Care Med. 2004 Jul;30(7):1502
pubmed: 15185067
JAMA. 2016 Feb 23;315(8):788-800
pubmed: 26903337
J Emerg Med. 2011 Jul;41(1):97-101
pubmed: 20189741
Anaesth Intensive Care. 2010 Sep;38(5):930-4
pubmed: 20865881
Intensive Care Med. 2014 Jul;40(7):950-7
pubmed: 24811940
Trials. 2015 May 24;16:226
pubmed: 26003545
N Engl J Med. 1965 Aug 19;273:401-9
pubmed: 14328102
Anesth Analg. 2015 Nov;121(5):1231-9
pubmed: 26332856
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Crit Care. 2011;15(6):R262
pubmed: 22044724
Lancet Respir Med. 2016 Nov;4(11):882-893
pubmed: 27717861
Eur Respir J. 2019 Oct 17;54(4):
pubmed: 31346004
Crit Care. 2013 Mar 12;17(2):123
pubmed: 23510269
Sci Data. 2016 May 24;3:160035
pubmed: 27219127
J Am Med Inform Assoc. 2018 Jan 1;25(1):32-39
pubmed: 29036464
Eur Respir J. 2019 Oct 17;54(4):
pubmed: 31624130
Respir Care. 2014 Jul;59(7):1025-33
pubmed: 24255160
Crit Care Nurse. 2007 Oct;27(5):48-55; quiz 56
pubmed: 17901460
N Engl J Med. 1963 Nov 7;269:991-6
pubmed: 14059732
Int J Physiol Pathophysiol Pharmacol. 2020 Apr 15;12(2):51-57
pubmed: 32419900
BMC Anesthesiol. 2014 Oct 01;14:85
pubmed: 25302048
BMC Anesthesiol. 2011 Nov 21;11:22
pubmed: 22103561